Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Patiromer Sorbitex Calcium
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Veltassa® (patiromer) Approved in Japan For The Treatment of Adults with Hyperkalemia
Details : Veltassa (patiromer sorbitex calcium) is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.
Product Name : Veltassa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Patiromer Sorbitex Calcium
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation ...
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcium
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Calcium
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg
Details : Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Astellas Pharma
Deal Size : $130.3 million
Deal Type : Agreement
Astellas Transfers Dificlir in Europe, Middle East, Africa and selected CIS to Tillotts Pharma
Details : Under the agreement, Astellas Europe will transfer its marketing authorizations for Dificlirtm (generic name: fidaxomicin) tablets for Clostridium difficile infections in Europe, Middle East, Africa and selected Commonwealth of Independent States to Till...
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 27, 2020
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Astellas Pharma
Deal Size : $130.3 million
Deal Type : Agreement
Lead Product(s) : Acotiamide HCl Hydrate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Acotiamide HCl Hydrate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Agreement
Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical
Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exploratory Study of ZG-801 for the Treatment of Hyperkalemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 10, 2019
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial to Optimally Show the Pharmacological Action of Z-100
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 23, 2018
Lead Product(s) : Metronidazole Benzoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2016
Lead Product(s) : Metronidazole Benzoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable